Study
Emerging strategies, applications and challenges of targeting NAD+ in the clinic
Multi-author review of NAD+ supplementation trials: safety is consistent, bioavailability and efficacy evidence remain thin.
Summary Can NAD+ treatments improve memory and slow Alzheimer’s disease? Show / hide ↓
Researchers ran early-stage clinical trials, meaning small, preliminary studies in people, involving patients with early Alzheimer’s disease. They tested NAD+ precursors, substances the body can use to make NAD+, but the report does not say which product or dose was used. Some participants showed improvements in memory, movement, or measures of metabolic health, which covers how the body handles energy. The report does not provide the number of participants, how long the trials lasted, or enough detail to know whether the treatments caused these changes.
What this means for you: This is not enough evidence to buy NAD+ supplements or use them to treat or prevent Alzheimer’s disease. Larger, longer, well-designed studies are needed, and supplements may not match the treatments used in these trials.
early evidenceEarly findings from clinical trials of NAD+ precursors showed promise for slowing aging and fighting Alzheimer's disease, with some trials reporting improvements in memory, physical movement, and metabolic health. This is significant because Alzheimer's disease has no effective disease-modifying treatment, and NAD+ precursors (NMN, NR) are widely available as supplements. The trials are early-phase, meaning small sample sizes and short durations. The mechanism involves NAD+ depletion in the brain during aging and neurodegeneration, which impairs mitochondrial function and DNA repair. While promising, these are early findings and should not be interpreted as evidence that NAD+ supplements treat or prevent Alzheimer's. The source did not specify which NAD+ precursor was tested, the dose, or the trial design.
NAD+ precursors show early promise in improving memory, physical movement, and metabolic health.
Early-phase trials, small samples. Not yet evidence for clinical Alzheimer's treatment. Specific precursor, dose, and trial design not specified in source.
From this page back to the goal it moves.
Cited by
3 encyclopedia entries reference this study.